Polymer-VWF Conjugates for Prolonged Protein Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bleeding disorders associated with von Willebrand factor (VWF) and factor VIII (FVIII) deficiencies have limitations due to the short in vivo half-life of these proteins, requiring frequent dosing and not adequately addressing the stabilization and prolonged circulation of VWF and FVIII in patients.
Innovation Solution
A proteinaceous construct comprising plasmatic or recombinant VWF bound to physiologically acceptable polymer molecules, which forms a complex with FVIII, prolonging the in vivo half-life of both proteins through pharmacological mechanisms that allow for controlled release and stabilization, thereby enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VWF or FVIII replacement therapy is used to treat bleeding disorders, then therapeutic efficacy is improved, but the short in vivo half-life requires frequent dosing
Solution Approach 1:
The patent creates a composite molecule by conjugating VWF or FVIII to polymers with prolonged half-life characteristics. This composite construct combines the therapeutic activity of the protein with the extended circulation time of the polymer, resolving the contradiction between therapeutic efficacy and duration of action.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of VWF or FVIII by changing their molecular structure through polymer conjugation. This alters the half-life parameter from hours to days, enabling less frequent dosing while maintaining therapeutic efficacy.
2Reliability
If frequent dosing is used to maintain therapeutic levels, then therapeutic efficacy is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
By creating a polymer-protein conjugate with extended half-life, the patent reduces the dosing frequency requirement from multiple times per week to less frequent administration, thereby improving ease of operation while maintaining therapeutic level maintenance through the prolonged circulation of the conjugate.
3Duration of action of moving object
If VWF is used to stabilize FVIII, then FVIII half-life is prolonged, but the complexity of the treatment system increases
Solution Approach 1:
The patent creates a simplified monocomponent therapy (polymer-VWF or polymer-FVIII conjugate) that inherently provides both the stabilization and prolonged half-life functions, eliminating the need for separate VWF and FVIII products and reducing treatment system complexity.
Solution Approach 2:
The patent merges the functions of VWF (stabilization) and extended half-life characteristics into a single conjugate molecule, combining multiple therapeutic effects into one agent rather than requiring multiple separate treatments.
Data Source
AI summary
The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.